Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15650721 | 0.81 | LRRK2 (0.44) | — | |
| SCHEMBL17076886 | 0.80 | LRRK2 (0.34) | LMNAALDH1A1MAPT | |
| SCHEMBL22280315 | 0.77 | ALDH1A1 (0.35) | LMNAADORA3KDM4EPKMADORA2A | |
| SCHEMBL30604554 | 0.75 | L3MBTL1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL4561198 | 0.75 | GPR35 (0.37) | PKMALDH1A1MAPT | |
| SCHEMBL20801702 | 0.74 | — | — | |
| SCHEMBL24708463 | 0.71 | LMNA (0.33) | LMNAADORA3KDM4EPKMADORA2A | |
| SCHEMBL17076907 | 0.70 | LRRK2 (0.40) | — | |
| SCHEMBL20555210 | 0.69 | CYP4F2 (0.36) | LMNAADORA3KDM4EADORA2AADORA1 | |
| SCHEMBL12837966 | 0.68 | NOS1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497387-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | DENALI THERAPEUTICS INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240158371-A1 | PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS | DENALI THERAPEUTICS INC. | 2024-05-16 | — | — | US | disclosed |
| EP-3727377-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS | DENALI THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| US-11834438-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834438-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834438-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | DENALI THERAPEUTICS INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-10-26 | — | — | US | disclosed |
| CN-112088003-B | Process for preparing pyrimidinyl-4-aminopyrazole compounds | 戴纳立制药公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3966206-B1 | HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| WO-2014060112-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2638031-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062783-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834438-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | LRRK2, PARK7, PINK1 | LMNA 1738/4885ADORA3 2062/4885KDM4E 1533/4885 |
| US-20240158371-A1 | PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS | LRRK2, PARK7, PINK1 | LMNA 1738/4885ADORA3 2062/4885KDM4E 1533/4885 |
| US-12497387-B2 | Process for the preparation of pyrimidinyl-4-aminopyrazole compounds | LRRK2, PARK7, PINK1 | LMNA 1738/4885ADORA3 2062/4885KDM4E 1533/4885 |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LMNA 4212/4885ADORA3 39/4885KDM4E 2581/4885 |
| US-20230338376-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | LMNA 2982/4885ADORA3 2783/4885KDM4E 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.